KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $145.0 million.

  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) rose 1471.52% to $145.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $543.7 million, marking a year-over-year increase of 1259.06%. This contributed to the annual value of $543.7 million for FY2025, which is 1259.06% up from last year.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) amounted to $145.0 million in Q4 2025, which was up 1471.52% from $136.7 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $145.0 million during Q4 2025, with a 5-year trough of $67.4 million in Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $104.2 million (2023), whereas its average is $103.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 464.14% in 2022, then surged by 3857.53% in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $74.5 million in 2021, then skyrocketed by 34.36% to $100.1 million in 2022, then rose by 12.89% to $113.0 million in 2023, then rose by 11.86% to $126.4 million in 2024, then grew by 14.72% to $145.0 million in 2025.
  • Its last three reported values are $145.0 million in Q4 2025, $136.7 million for Q3 2025, and $135.1 million during Q2 2025.